2025: The 2019/24 Cochrane Larun review Exercise Therapy for CFS - including IAG, campaign, petition, comments and articles

Discussion in '2021 Cochrane Exercise Therapy Review' started by S4ME News, Dec 22, 2024.

  1. Peter Trewhitt

    Peter Trewhitt Senior Member (Voting Rights)

    Messages:
    4,468
    Presumably members of Cochrane are entitled to express scientific views, unless they are hiding conflicts of interest or acting in any underhand fashion. However it may be that exerting covert pressure through the Cochrane Board to block genuine scientific investigation and obscure bad analysis is more dubious.
     
    Kitty, bobbler, Trish and 2 others like this.
  2. Medfeb

    Medfeb Senior Member (Voting Rights)

    Messages:
    607
    I understand the point of view being expressed re criteria. I just disagree
     
    Kitty, bobbler, Hutan and 2 others like this.
  3. rvallee

    rvallee Senior Member (Voting Rights)

    Messages:
    14,079
    Location:
    Canada
    Last year a major review of exercise studies for depression was published. It mostly showed a total bust, at best that the data are very unreliable, do not even come close to the overhyped claims of the last few decades. There is simply nothing reliable behind those claims, they were made out of nothing based on vibes and feels.

    And it changed nothing. It's still argued that exercise is great for depression, even pointing at the review that doesn't support this. There are still people, 'experts', going around 'teaching' about how to implement exercise programs for depression, how to do it safely, all the usual superficial all-style-no-substance we are used to.

    The problem is far bigger than just us. This is the main methodology used by the likes of Cochrane and it created the same mess: overhyped claims made before any data were available continue to be made despite having been thoroughly debunked, just because the industry can't accept they have been systematically failing for decades.

    I really don't know we we can affect that, but this is the scale of the problem. It's the entire clinical rehab and copy-paste-of-cheap-trials industries that have basically painted themselves in a corner, and having managed to work out a version of Zeno's paradox, painting ever-smaller lines closer to the corner, they have nowhere else to go. The lines are already too small to be visible, they just keep repainting the last line and no one in the industry cares. They paint lines, they don't ask questions.

    They can't let this go. They won't. Because it's their whole fake-ass industry that would be exposed as a giant con. Because every single institution and organization tasked with avoiding garbage like this failed, enabled, even encouraged this to go on, cheering it the whole way.
     
    JemPD, Hutan, Kitty and 2 others like this.
  4. rvallee

    rvallee Senior Member (Voting Rights)

    Messages:
    14,079
    Location:
    Canada
    And in addition to valid questions about MAGENTA, there's also the abandoned individual patient data review that was supposed to use PACE data, individualized instead of pooled. Guaranteed that they abandoned it because they started looking at the data, and found that there is no way they could spin this into a positive. If they could have, they absolutely would. They didn't drop it for a good reason.

    A fully independent investigation here would find malfeasance on a grand scale. So the best they try to do is simply to bury the whole thing and wait for us to die while they go through another label-replacement cycle. I'm guessing they are probably ignorant, or at least apathetic enough, to actually believe that this is just a fad that will blow over one day, that our "small vocal minority of activists" are just some phase, or whatever. It's easy to maintain something like this when no one keeps accurate data anywhere.
     
    SNT Gatchaman, Hutan, Kitty and 2 others like this.
  5. Jonathan Edwards

    Jonathan Edwards Senior Member (Voting Rights)

    Messages:
    15,972
    Location:
    London, UK
    Something that I don't actually know, despite having been a co-author of a Cochrane Review, is whether or not Cochrane Reviews actually cost Cochrane anything to get done. I don't remember my senior author getting funding from Cochrane but she may have done. My impression was that people proposed to Cochrane that they did a review and if Cochrane thought it was needed they said yes. Funding for salaries for reviewers came from elsewhere.

    @Caroline Struthers might know much more.

    If the people who agreed to do a new review were not being paid then it is unclear to me what justification Cochrane would have for now saying no thanks when the review was invited 5 years ago and nothing has made it less relevant.
     
    Hutan, Kitty, bobbler and 3 others like this.
  6. Hutan

    Hutan Moderator Staff Member

    Messages:
    30,776
    Location:
    Aotearoa New Zealand
    My understanding is that, in this particular case, some of the people on the writing group were Cochrane staff, so they were being paid a salary and the review was part of their day job. When funding was pulled to Cochrane, some/all of these people may have lost their jobs. I don't know if the other members of the writing group and the IAG were paid anything, if they were, I doubt it was more than expenses. @Medfeb will know.

    However, possibly the Cochrane writing group staff would have been willing to continue, to do the work for free. Perhaps Hilda was being paid, even so, she also may have been willing to work for free. If any of these people were not willing to work for free, others could have been found who were. Or there could have been crowd funding. There were options.

    The issue that Cochrane I think are mostly referring to with respect to not enough resources seems to be around the costs of overseeing the project and editorial input within Cochrane itself. So, the time of Karla Soares-Weisser, for example, in reviewing the protocol, negotiating any changes, dealing with the inputs from the IAG, reviewing a drafted new review, negotiating changes, keeping the psychosomatic crowd happy, dealing with the flak when the new review was published.... Perhaps they were bundling the dealing with all of the complaints about the Larun review in that as well, although of course that should be a separate matter.

    It's not a well founded reason, because the problems (e.g. having to please the psychosomatic people and so needing to interfere in the review process) are of their own making. Basically, they just could not be bothered with the hassle of a new review and didn't think anyone worth bothering about would be upset if it did not proceed. So, their thinking seems to be, label the 2019 review as 2024, draw a line under the whole matter (complaints about the old review, a new review process), put their fingers in their ears when anyone mentions ME/CFS, and carry on.
     
    Peter Trewhitt likes this.
  7. Peter Trewhitt

    Peter Trewhitt Senior Member (Voting Rights)

    Messages:
    4,468
    At one point Hilda seemed to say that Cochrane had started paying her. That was after one of the various hiatuses presumably meaning she was not paid before then.

    I can’t remember if it was late 2023 or not.
     
    Hutan likes this.
  8. Hutan

    Hutan Moderator Staff Member

    Messages:
    30,776
    Location:
    Aotearoa New Zealand
    Yes, she definitely was being paid by Cochrane at some point, but also not being paid at others. Perhaps she was being paid for some part of 2024? If she was, that may have contributed to her belief that Cochrane was supporting the new review process and everything was back on track.
     
    NelliePledge and Peter Trewhitt like this.

Share This Page